/ , ()

-/ ,
()
A.. , .. , . , .. , .. ,
B.. , .. , ..
-
. .. ()
, - . . . , .
: , , , , , -, .
METHODS OF EXTRACORPOREAL BLOOD CORRECTION IN THE TREATMENT OF COMPLICATIONS AFTER RENAL
TRANSPLANTATION ISCHEMIC/REPERFUSION INJURY, TRANSPLANT REJECTION
(review)
A.V. Vatazin, A.B. Zulkarnayev, M. Krstic, R.O. Kantariya, D.V. Artemov, V.A. Fedulkina, A.A. Sinyutin, K.K. Gubarev
M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)
As a result of the progress in transplantation technique, the outcomes of renal transplantation have been significantly improved. But further, the cadaveric renal graft is inevitably affected by ischemia and later subject to reperfusion injury. Graft rejection growth leads to further impairment of the transplanted kidney function. For prevention and treatment of complications associated with the renal transplantation procedure, the xtracorporeal hemocorrection is increasingly used. Our investigation presents a review of the modern prospective techniques to correct ischemic and reperfusion lesions and offers methods for treatment of graft rejection.
Key words: ischemia, reperfusion, renal transplantation, hemofiltration, cytokine sorption, plasmapheresis, cascade plasma filtration.
/- (), , .
- - , . -
. , . -
.

, , , , , , - . [10, 37].
, ,
- , , . (, , , , .) [20, 42].
. - : , , .
- - . , , , , [36].
- . , , [19].
, -
- , [46, 48]. - , , . . 1^1 . [34], . . , , , . , , .
. : -, -1, -2, -6 -10, . [23, 29]. . , 1_. !-1 . [15] , -2 - . .1. . [6] , -1 - ^67653 , , , .
. . . . [27], - , . , , , -, . --65, -3 . , .

. 1_. . , - [12, 13]. - ( , ) , [8]. .. . , : , -6, -9, -16 -1 [11]. , , . , , - .
( -/ ) : 2-, -6, , - . : - [22, 28, 43, 52]. -. , , , . : - [7].
, . () - (), , -1, -1 - [5, 16]. , [14, 24, 39].
, . - . - ()
, - - , . , [35, 40].
- . , . , [19, 42].
D. Kaminska . , /, - [23]. - -6 -. . , .
- high flux. : . , , , , . , , , -, [20, 33].
. , , , . , ( - ) , - 3, 5 D-, - . -
. [3, 9, 26].
, : , . - 10 , -. - . . T. Hira-no . () -, . , , [19]. ( 3-10 ), .
J.F. Winchester . . 2-, , D- (-1, -6, -10, -18 ) [51]. , .
, , , , . , , .

, , (, , .), .
, , -
. . - . -, -1, -2, -6 -10 [23]. , - . .
- , . , , , .
- . , - . : , , , .
- . - . . : , , , , . - - [32]. - .
( -)
. , - . .
- [1, 2, 41, 50]. .
. , - , , ї, , . [4, 21, 49]. - . , , . , : , , 1, , [4, 25, 49].
, . : , ; ; - (600-1000 ) . , . , -. , -
[30, 38].
- , [17, 18, 44]. ( ) , . G M, , , - , 2-. - :
- ( - ї );
- (, , );
- ( );
- ( , ) [18, 44].
, ABO- - [17, 18, 31, 45, 47]. , - - -. - 42 . IgG 59,4%, IgM - 69,3%. - [18].
(- -) 0- . -
39 . - , 1:32. 97%, [44].
, :
- de novo - ;
- ;
- .
, - - . , . , , , . .

1. .., .., .. . // . . . . 2009. 1. .28-33.
2. .., .., .. . // . . . . 2003. 3. .21-30.
3. Akahori T.A., Sho M., Kashizuka H. et al. Novel CCR5/CXCR3 antagonist protects intestinal ischemia/reperfusion injury // Transplant. Proc. 2006. V.38, No.10. P.3366-3368.
4. Bartel G., Schwaiger E., Bohmig G.A. Prevention and treatment of alloantibody-mediated kidney transplant rejection // Transplant. Int. 2011. V.24, No.12. P.1142-1155.
5. Calo L.A., Naso A., Davis P.A. et al. Hemodiafiltration with online regeneration of ultrafiltrate: effect on heme-oxygenase-1 and inducible subunit of nitric oxide synthase and implication for oxidative stress and inflammation // Artif. Organs. 2011. V.35, No.2. P.183-187.
6. Cau J., Favreau F., Zhang K. et al. FR167653 improves renal recovery and decreases inflammation and fibrosis after renal ischemia reperfusion injury // J. Vasc. Surg. 2009. V.49, No.3. P.728-740.
7. Chrzanowska M., Kaminska J., Gfyda M. et al. Antioxidant capacity in renal transplant patients // Pharmazie. 2010. V.65, No.5. P.363-366.
8. Cicco G., Panzera P.C., Catalano G., Memeo V. Microcirculation and reperfusion injury in organ transplantation // Adv. Exp. Med. Biol. 2005. V.566. P.363-373.
9. Damman J., Schuurs T.A., Ploeg R.J., Seelen M.A. Complement and renal transplantation: from donor to recipient // Transplantation. 2008. V.85, No.7. P.923-927.
10. Davenport A. The brain and the kidney-organ cross talk and interactions // Blood Purif. 2008. V.26, No.6. P.526-536.
11. De Vries D.K., Lindeman J.H., Ringers J. et al. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation // Am. J. Transplant. 2011. V.11, No.5. P.1064-1070.
12. Domanski L., Pawlik A., Safranow K. et al. Purine and cytokine concentrations in the renal vein of the allograft during reperfusion // Transplant. Proc. 2007. V.39, No.5. P.1319-1322.
13. Domanski L., Safranow K., Ostrowski M. et al. Oxypurine and purine nucleoside concentrations in renal vein of allograft are potential markers of energy status of renal tissue // Arch. Med. Res. 2007. V.38, No.2. P.240-246.
14. Dursun E., Dursun B., Suleymanlar G., Ozben T. Carbonyl stress in chronic renal failure: the effect of haemodialysis // Ann. Clin. Biochem. 2005. V.42 (Pt.1). P.64-66.
15. El-AsirL., Wilson C.H., Talbot D. Interleukin 2 receptor blockers may directly inhibit lymphocyte mediated ischaemia reperfusion injury // Transplant. Int. 2005. V.18, No.9. P.1116.
16. Filiopoulos V., Hadjiyannakos D., Metaxaki P. et al. Inflammation and oxidative stress in patients on hemodiafiltration // Am. J. Nephrol. 2008. V.28, No.6. P.949-957.
17. Gungor O., Sen S., Kircelli F. et al. Plasmapheresis therapy in renal transplant patients: five-year experience // Transplant. Proc. 2011. V.43, No.3. P.853-857.
18. Higgins R., Lowe D., Hathaway M. et al. Double filtration plasmapheresis in antibody-incompatible kidney transplantation // Ther. Apher. Dial. 2010. V.14, No.4. P.392-399.
19. Hirano T., Hirasawa H., Oda S. et al. Modulation of polymorphonuclear leukocyte apoptosis in the critically ill by removal of cytokines with continuous hemodiafiltration // Blood Purif. 2004. V.22, No.2. P.188-197.
20. Honor P.M., Joannes-Boyau O., Gressens B. Blood and plasma treatments: high-volume hemofiltration-a global view // Contrib. Nephrol. 2007. No.156. P.371-386.
21. Ibernon M., Gil-Vernet S., Carrera M. et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation // Transplant. Proc. 2005. V.37, No.9. P.3743-3745.
22. Joo D.J., Huh K.H., Cho Y. et al. Change in serum lipid peroxide as an oxidative stress marker and its effects on kidney function after successful kidney transplantation // Transplant. Proc. 2010. V.42, No.3. P.729-732.
23. Kaminska D., Tyran B., Mazanowska O. et al. Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysis // Transplantation. 2007. V.84, No.9. P.1118-1124.
24. Karamouzis I., Sarafidis P.A., Karamouzis M. et al. Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease // Am. J. Nephrol. 2008. V.28, No.3. P.397-404.
25. Lennertz A., Fertmann J., Thomae R. et al. Plasmapheresis in C4d-positive acute humoral rejection following kidney transplantation: a review of 4 cases // Ther. Apher. Dial. 2003. V.7, No.6. P.529-535.
26. Lewis A.G., Khl G., Ma Q. et al. Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival // Clin. Exp. Immunol. 2008. V.153, No.1. P.117-126.
27. Li Z, Nickkholgh A., Yi X. et al. Melatonin protects kidney grafts from ischemia/reperfusion injury through inhibition of NF-kB and apoptosis after experimental kidney transplantation // J. Pineal. Res. 2009. V.46, No.4. P.365-372.
28. Libetta C., Sepe V., Esposito P. et al. Oxidative stress and inflammation: Implications in uremia and hemodialysis // Clin. Biochem. 2011. V.44, No.14-15. P.1189-1198.
29. Lutz J., Thrmel K., Heemann U. Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation // J. Inflamm. (Lond). 2010. V.7. P.27.
30. MarksS. Therapeutic plasmapheresis: recognizing complications as soon as possible // Pflege Z. 2005. V.58, No.11. P.696-698.
31. Matsuo N., Yamamoto H., Kobayashi A. et al. A case of accelerated acute rejection after ABO-compatible living unrelated kidney transplantation // Clin. Transplant. 2009. Suppl.20. P.23-26.
32. Naesens M., Lerut E., Sarwal M. et al. Balancing efficacy and toxicity of kidney transplant immunosuppression // Transplant. Proc. 2009. V.41, No.8. P.3393-3395.
33. Nakada T.A., Hirasawa H., Oda S. et al. Blood purification for hypercytokinemia // Transfus. Apher. Sci. 2006. V.35, No.3. P.253-264.
34. Nowacki M., Drozdzik M., Safranow K. et al. Does calcium channel blocker improvement of perfusion impact the functioning of kidney graft in early period after transplantation? // Transplant. Proc. 2008. V.40, No.4. P.1056-1058.
35. Oda S., Hirasawa H., Shiga H. et al. Continuous hemofiltra-tion/hemodiafiltration in critical care // Ther. Apher. 2002. V.6, No.3. P.93-98.
36. OpelzG. Very short ischaemia is not the answer // Nephrol. Dial. Transplant. 2002. V.17, No.5. P.715-716.
37. PownerD.J. Effects of gene induction and cytokine production in donor care // Prog. Transplant. 2003. V.13, No.1. P.9-14.
38. Pruijm M.T., Vogt B., Cherpillod A. Plasmapheresis, a safe treatment when applied to the correct indication and with awareness of the complications // Ned. Tijdschr. Ge-neeskd. 2008. V.152, No.42. P.2261-2266.
39. Pupim L.B., Himmelfarb J., McMonagle E. et al. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress // Kidney Int. 2004. V.65, No.6. P.2371-2379.
40. Saito A. Current progress in blood purification methods used in critical care medicine // Contrib. Nephrol. 2010. V.166. P.100-111.
41. Shah A., Nadasdy T., Arend L. et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin // Transplantation. 2004. V.77, No.9. P.1399-1405.
42. Simmons E.M., Himmelfarb J., Sezer M.T. et al. Plasma cy-tokine levels predict mortality in patients with acute renal failure // Kidney Int. 2004. V.65, No.4. P.1357-1365.
43. Simmons E.M., Langone A., Sezer M.T. et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients // Transplantation. 2005. V.79, No.8. P.914-919.
44. Tanabe K. Double-filtration plasmapheresis // Transplantation. 2007. V.84 (Suppl.12). P.S30-S32.
45. Tanabe K., Tokumoto T., Ishida H. et al. ABO-incompatible renal transplantation at Tokyo Women's Medical University // Clin. Transplant. 2003. P.175-181.
46. Treska V., Kobr J., Hasman D. et al. Ischemia-reperfusion injury in kidney transplantation from non-heart-beating donor-do antioxidants or antiinflammatory drugs play any role? // Bratisl. Lek. Listy. 2009. V.110, No.3. P.133-136.
47. Uchida J., Iwai T., Kato M. et al. A novel approach to successful ABO-incompatible high-titer renal transplantation // Transplant. Proc. 2008. V.40, No.7. P.2285-2288.
48. Uji M., Inoue S., Furuya H. Sustained hypertension at reperfusion of the transplanted kidneys from the non-heart beating donor // Anesth. Analg. 2006. V.102, No.3. P.976.
49. Ward D.M. Conventional apheresis therapies: A review // J. Clin. Apher. 2011. V.26, No.5. P.230-238.
50. White B. Plasmapheresis in the treatment of acute vascular rejection: an experience on a dialysis unit // J. Ren. Care. 2006. V.32, No.4. P.208-209.
51. Winchester J.F., Silberzweig J., Ronco C. et al. Sorbents in acute renal failure and end-stage renal disease: middle molecule and cytokine removal // Blood Purif. 2004. V.22, No.1. P.73-77.
52. Zahmatkesh M., Kadkhodaee M., Mahdavi-Mazdeh M. et al. Oxidative stress status in renal transplant recipients // Exp. Clin. Transplant. 2010. V.8, No.1. P.38-44.